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Dear Editor,
We read with interest the article by Rehman et al. on post-
artesunate hemolysis (PADH).1 Hemolysis is indeed commonly
associated with the class of artemisinin drugs when used for the
treatment of severe malaria. Their review conﬁrmed the high
incidence of this adverse event related to the mode of action of
artemisinins and the physiological role of the spleen.2 As the
authors wisely pointed out, delayed hemolysis should not
jeopardize the deployment of artesunate as the ﬁrst-line treatment
of severe malaria worldwide. While PADH is indeed rarely (if ever)
fatal, artesunate signiﬁcantly reduces mortality as compared to
quinine, markedly so in patients with parasitemia greater than 10%
on admission.3 Importantly, PADH has been further characterized
by a pathophysiological study in travelers treated with artesunate
for severe malaria.4 Early peak concentrations of circulating once-
infected erythrocytes are predictive for the occurrence of PADH
and may therefore serve as a future candidate marker for PADH.
Rehman et al. referred to different anemia patterns in their analysis
of published reports. This deﬁnition was based on initial
descriptions by Zoller et al.5 and on a more reﬁned deﬁnition
proposed in a closed meeting organized by the Medicine for
Malaria Venture (MMV) in March 2013 in Vienna (http://www.
mmv.org/sites/default/ﬁles/uploads/docs/events/2013/
InjectableArtesunateExpertGroupMeeting.pdf)6 and later pub-
lished in the above mentioned pathophysiological paper.4Whereas
initial reports were acknowledged in the article by Rehman et al.,
the optimized nosological classiﬁcation was not referenced in the
manuscript. This omission is likely due to the disclosure in the
MMV report (which became publicly available in 2013) of the then
unpublished, optimized case deﬁnition proposed by our group,
without precise referencing of the source of that particular set of
information. Sharing unpublished results or concepts during
subject-speciﬁc meetings, like the one efﬁciently organized by
MMV in Vienna, is important as it allows the malaria community to
adapt rapidly and efﬁciently to new problems with a public health
impact. When reports of such meetings carefully acknowledge all
respective contributions, this ultimately contributes to maintain-
ing rich exchanges between attendees.http://dx.doi.org/10.1016/j.ijid.2014.12.048
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).References
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